Hazard ratios for all-cause mortality by category of ESA responsiveness based on a combination of ESA dosage and hemoglobin level.

<p>Adjusted model included for age, gender, diabetes mellitus, previous cardiovascular disease history, duration of dialysis, serum level of iron, ferritin, albumin, intact PTH, hsCRP, total cholesterol and Kt/V.</p><p>^aMedian value of ESA dose in hemodialysis patients</p><p>^bMedian value of ESA dose in peritoneal dialysis patients.</p><p>ESA, erythropoiesis-stimulating agent; Hb, hemoglobin; N, number of patients; HD, hemodialysis; PD, peritoneal dialysis; HR, hazard ratios; CI, confidence interval; P, P-value.</p><p>Hazard ratios for all-cause mortality by category of ESA responsiveness based on a combination of ESA dosage and hemoglobin level.</p

Kaplan-Meier plot of patient survival by tertiles of erythropoietin resistance index in (A) hemodialysis and (B) peritoneal dialysis patients.

<p>Kaplan-Meier plot of patient survival by tertiles of erythropoietin resistance index in (A) hemodialysis and (B) peritoneal dialysis patients.</p

Cox regression analysis of all-cause mortality.

<p>^aAdjusted for age, gender, diabetes mellitus, previous cardiovascular disease history, duration of dialysis, serum level of iron, ferritin, albumin, intact PTH, hsCRP, total cholesterol and single-pool Kt/V.</p><p>^bAdjusted for age, gender, diabetes mellitus, previous cardiovascular disease history, duration of dialysis, serum level of iron, ferritin, albumin, intact PTH, hsCRP, total cholesterol and weekly Kt/V.</p><p>HD, hemodialysis; hsCRP, high sensitivity C-reactive protein; PD, peritoneal dialysis; ERI, erythropoietin resistance index; HR, hazard ratios; CI, confidence interval; P, P-value.</p><p>Cox regression analysis of all-cause mortality.</p

Causes of death of the study population by tertiles of ERI.

<p>ERI, erythropoietin resistance index; HD, hemodialysis; PD, peritoneal dialysis.</p><p>Causes of death of the study population by tertiles of ERI.</p

Clinical characteristics of the study population according to tertiles of ERI.

<p>Data are expressed as means ± SD, medians (interquartile range) or numbers (percentages), as appropriate.</p><p>ERI, erythropoietin resistance index; BP, blood pressure; CVD, cardiovascular diseases; CCI, Charlson co-morbidity index; Ccr, creatinine clearance; ESA, erythropoiesis-stimulating agent; HD, hemodialysis; hsCRP, high sensitivity C-reactive protein; IV, intravenous; Kt/V: K, dialyzer clearance; t, time; V, volume of water a patient’s body contains; PD, peritoneal dialysis; PTH, parathyroid hormone; SGA, subject global assessment; TSAT, transferrin saturation.</p><p>Clinical characteristics of the study population according to tertiles of ERI.</p

Clinical Characteristics of the Study Population According to Dialysis Modality.

<p>Data are expressed as means SD, medians (interquartile range) or numbers (percentages), as appropriate.</p><p>BP, blood pressure; CVD, cardiovascular diseases; CCI, Charlson co-morbidity index; Ccr, creatinine clearance; ESA, erythropoiesis-stimulating agent; HD, hemodialysis; hsCRP, high sensitivity C-reactive protein; IV, intravenous; Kt/V: K, dialyzer clearance; t, time; V, volume of water a patient’s body contains; PD, peritoneal dialysis; PTH, parathyroid hormone; SGA, subject global assessment; TSAT, transferrin saturation.</p><p>Clinical Characteristics of the Study Population According to Dialysis Modality.</p